litlas
Log inCreate account

Hiroaki Mitsuya

Active 1978–2024

143
Papers
25,609
Citations
88
h-index
141
i10-index

Citations

Citations per year for Hiroaki Mitsuya1979: 1 citations1980: 2 citations1982: 6 citations1983: 3 citations1984: 5 citations1985: 13 citations1986: 39 citations1987: 165 citations1988: 146 citations1989: 193 citations1990: 231 citations1991: 178 citations1992: 239 citations1993: 145 citations1994: 135 citations1995: 108 citations1996: 94 citations1997: 87 citations1998: 110 citations1999: 89 citations2000: 89 citations2001: 86 citations2002: 104 citations2003: 100 citations2004: 150 citations2005: 102 citations2006: 120 citations2007: 108 citations2008: 108 citations2009: 132 citations2010: 84 citations2011: 96 citations2012: 81 citations2013: 90 citations2014: 63 citations2015: 74 citations2016: 64 citations2017: 37 citations2018: 49 citations2019: 207 citations2020: 304 citations2021: 588 citations2022: 699 citations2023: 340 citations2024: 378 citations2025: 103 citations2026: 11 citations1981: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,354 citing papers, 36.2% of this breakdownJapan: 421 citing papers, 6.5% of this breakdownChina: 414 citing papers, 6.4% of this breakdownUnited Kingdom: 358 citing papers, 5.5% of this breakdownGermany: 309 citing papers, 4.7% of this breakdownFrance: 273 citing papers, 4.2% of this breakdownItaly: 191 citing papers, 2.9% of this breakdownBelgium: 185 citing papers, 2.8% of this breakdownIndia: 161 citing papers, 2.5% of this breakdownCanada: 147 citing papers, 2.3% of this breakdownSpain: 136 citing papers, 2.1% of this breakdownAustralia: 116 citing papers, 1.8% of this breakdown
0%36.2%Other 22.1%

Institutions

Fields

  • Medicine53%
  • Immunology and Microbiology21.1%
  • Biochemistry, Genetics and Molecular Biology14.9%
  • Computer Science3.8%
  • Chemistry2.5%
  • Pharmacology, Toxicology and Pharmaceutics1%
  • Other3.7%

Topics

  • HIV Research and Treatment9.9%
  • HIV/AIDS drug development and treatment8.6%
  • SARS-CoV-2 and COVID-19 Research7.8%
  • COVID-19 Clinical Research Studies4.6%
  • HIV/AIDS Research and Interventions2.9%
  • Computational Drug Discovery Methods2.4%
  • Other63.8%

Coauthors

All papers

Open in search
  1. Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development

    Authors: Masaki Imai, Kiyoko Iwatsuki‐Horimoto, Masato Hatta, Samantha Loeber, Peter Halfmann, Noriko Nakajima, Tokiko Watanabe, Michiko Ujie, Kenta Takahashi, Mutsumi Ito, Shinya Yamada, Shufang Fan, S. Chiba, Makoto Kuroda, Lizheng Guan, K. Takada, Tammy Armbrust, Aaron Balogh, Yuri Furusawa, Moe Okuda, Hiroshi Ueki, Atsuhiro Yasuhara, Yuko Sakai‐Tagawa, Tiago J. S. Lopes, Maki Kiso, Seiya Yamayoshi, Noriko Kinoshita, Norio Ohmagari, Shin-ichiro Hattori, Makoto Takeda, Hiroaki Mitsuya, Florian Krammer, Tadaki Suzuki, Yoshihiro Kawaoka - National Academy of Sciences, Proceedings of the National Academy of Sciences 2020 cited by 1,169

  2. Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2

    Authors: Ryuta Uraki, Maki Kiso, Shun Iida, Masaki Imai, Emi Takashita, Makoto Kuroda, Peter Halfmann, Samantha Loeber, Tadashi Maemura, Seiya Yamayoshi, Seiichiro Fujisaki, Zhongde Wang, Mutsumi Ito, Michiko Ujie, Kiyoko Iwatsuki‐Horimoto, Yuri Furusawa, Ryan Wright, Zhenlu Chong, Seiya Ozono, Atsuhiro Yasuhara, Hiroshi Ueki, Yuko Sakai‐Tagawa, Rong Li, Yanan Liu, Deanna Larson, Michiko Koga, Takeya Tsutsumi, Eisuke Adachi, Makoto Saito, Shinya Yamamoto, Masao Hagihara, Keiko Mitamura, Tetsuro Sato, Masayuki Hojo, Shin-ichiro Hattori, Kenji Maeda, Riccardo Valdez, IASO study team, Pamela Bennett-Baker, Zijin Chu, Dawson Davis, Theresa Kowalski-Dobson, Ashley Eckard, Carmen Gherasim, Wolf Gremel, Kathleen Lindsey, David M. Manthei, Alyssa Meyers, Julio Zuniga Moya, Aaron Rico, Emily Stoneman, Victoria M. Blanc, Savanna Sneeringer, Lauren Warsinske, Moe Okuda, Jurika Murakami, Calvin Duong, Sucheta Godbole, Daniel C. Douek, Ken Maeda, Shinji Watanabe, Aubree Gordon, Norio Ohmagari, Hiroshi Yotsuyanagi, Michael Diamond, Hideki Hasegawa, Hiroaki Mitsuya, Tadaki Suzuki, Yoshihiro Kawaoka - Nature 2022 cited by 292

  3. Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant

    Authors: Emi Takashita, Noriko Kinoshita, Seiya Yamayoshi, Yuko Sakai-Tagawa, Seiichiro Fujisaki, Mutsumi Ito, Kiyoko Iwatsuki-Horimoto, Shiho Chiba, Peter Halfmann, Hiroyuki Nagai, Makoto Saito, Eisuke Adachi, David Sullivan, Andrew Pekosz, Shinji Watanabe, Kenji Maeda, Masaki Imai, Hiroshi Yotsuyanagi, Hiroaki Mitsuya, Norio Ohmagari, Makoto Takeda, Hideki Hasegawa, Yoshihiro Kawaoka - New England Journal of Medicine 2022 cited by 404

  4. A small molecule compound with an indole moiety inhibits the main protease of SARS-CoV-2 and blocks virus replication

    Authors: Shin-ichiro Hattori, Nobuyo Higashi‐Kuwata, Hironori Hayashi, Srinivasa Rao Allu, Jakka Raghavaiah, Haydar Bulut, Debananda Das, Brandon J. Anson, Emma K. Lendy, Yuki Takamatsu, Nobutoki Takamune, Naoki Kishimoto, Kazutaka Murayama, Kazuya Hasegawa, Mi Li, David A. Davis, Eiichi Kodama, Robert Yarchoan, Alexander Wlodawer, Shogo Misumi, Andrew D. Mesecar, Arun K. Ghosh, Hiroaki Mitsuya - Nature Communications 2021 cited by 192

  5. Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2

    Authors: Emi Takashita, Noriko Kinoshita, Seiya Yamayoshi, Yuko Sakai-Tagawa, Seiichiro Fujisaki, Mutsumi Ito, Kiyoko Iwatsuki-Horimoto, Peter Halfmann, Shinji Watanabe, Kenji Maeda, Masaki Imai, Hiroaki Mitsuya, Norio Ohmagari, Makoto Takeda, Hideki Hasegawa, Yoshihiro Kawaoka - New England Journal of Medicine 2022 cited by 292

  6. Indole Chloropyridinyl Ester-Derived SARS-CoV-2 3CLpro Inhibitors: Enzyme Inhibition, Antiviral Efficacy, Structure–Activity Relationship, and X-ray Structural Studies

    Authors: Arun K. Ghosh, Jakka Raghavaiah, Dana Shahabi, Monika Yadav, Brandon J. Anson, Emma K. Lendy, Shin-ichiro Hattori, Nobuyo Higashi‐Kuwata, Hiroaki Mitsuya, Andrew D. Mesecar - Journal of Medicinal Chemistry 2021 cited by 90

  7. Characterization of monocyte/macrophage subsets in the skin and peripheral blood derived from patients with systemic sclerosis

    Authors: Nobuyo Higashi‐Kuwata, Masatoshi Jinnin, Takamitsu Makino, Satoshi Fukushima, Yuji Inoue, Faith C. Muchemwa, Yuji Yonemura, Yoshihiro Komohara, Motohiro Takeya, Hiroaki Mitsuya, Hironobu Ihn - Arthritis Research & Therapy 2010 cited by 246

  8. Recent Drug Development and Medicinal Chemistry Approaches for the Treatment of SARS‐CoV‐2 Infection and COVID‐19

    Authors: Arun K. Ghosh, Jennifer L. Mishevich, Andrew D. Mesecar, Hiroaki Mitsuya - ChemMedChem 2022 cited by 48

  9. 4′-Ethynyl-2-fluoro-2′-deoxyadenosine (EFdA) Inhibits HIV-1 Reverse Transcriptase with Multiple Mechanisms

    Authors: Eleftherios Michailidis, Andrew D. Huber, Emily Ryan, Yee Tsuey Ong, Maxwell D. Leslie, Kayla B. Matzek, Kamalendra Singh, Bruno Marchand, Ariel N. Hagedorn, Karen A. Kirby, Lisa C. Rohan, Eiichi Kodama, Hiroaki Mitsuya, Michael A. Parniak, Stefan G. Sarafianos - Journal of Biological Chemistry 2014 cited by 118

  10. Identification of SARS-CoV-2 Mpro inhibitors containing P1’ 4-fluorobenzothiazole moiety highly active against SARS-CoV-2

    Authors: Nobuyo Higashi‐Kuwata, Kohei Tsuji, Hironori Hayashi, Haydar Bulut, Maki Kiso, Masaki Imai, Hiromi Ogata-Aoki, Takahiro Ishii, Takuya Kobayakawa, Kenta Nakano, Nobutoki Takamune, Naoki Kishimoto, Shin-ichiro Hattori, Debananda Das, Yukari Uemura, Yosuke Shimizu, Manabu Aoki, Kazuya Hasegawa, Satoshi Suzuki, Akie Nishiyama, Junji Saruwatari, Yukiko Shimizu, Yoshikazu Sukenaga, Yuki Takamatsu, K. Tsuchiya, Kenji Maeda, Kazuhisa Yoshimura, Shun Iida, Seiya Ozono, Tadaki Suzuki, Tadashi Okamura, Shogo Misumi, Yoshihiro Kawaoka, Hirokazu Tamamura, Hiroaki Mitsuya - Nature Communications 2023 cited by 45

  11. PDK1 inhibition is a novel therapeutic target in multiple myeloma

    Authors: Saori Fujiwara, Yawara Kawano, Hiromichi Yuki, Yutaka Okuno, Kisato Nosaka, Hiroaki Mitsuya, Hironobu Hata - British Journal of Cancer 2012 cited by 139

  12. Structural basis of HIV inhibition by translocation-defective RT inhibitor 4′-ethynyl-2-fluoro-2′-deoxyadenosine (EFdA)

    Authors: Zhe Salie, Karen A. Kirby, Eleftherios Michailidis, Bruno Marchand, Kamalendra Singh, Lisa C. Rohan, Eiichi Kodama, Hiroaki Mitsuya, Michael A. Parniak, Stefan G. Sarafianos - National Academy of Sciences, Proceedings of the National Academy of Sciences 2016 cited by 110

  13. Comparison of Rapid Antigen Tests for COVID-19

    Authors: Seiya Yamayoshi, Yuko Sakai‐Tagawa, Michiko Koga, Osamu Akasaka, Ichiro Nakachi, Hidefumi Koh, Kenji Maeda, Eisuke Adachi, Makoto Saito, Hiroyuki Nagai, Kazuhiko Ikeuchi, Takayuki Ogura, Rie Baba, Kensuke Fujita, Takahiro Fukui, Fumimaro Ito, Shin-ichiro Hattori, Kei Yamamoto, Takato Nakamoto, Yuri Furusawa, Atsuhiro Yasuhara, Michiko Ujie, Shinya Yamada, Mutsumi Ito, Hiroaki Mitsuya, Norio Omagari, Hiroshi Yotsuyanagi, Kiyoko Iwatsuki‐Horimoto, Masaki Imai, Yoshihiro Kawaoka - Viruses 2020 cited by 226

  14. Antibody titers against SARS-CoV-2 decline, but do not disappear for several months

    Authors: Seiya Yamayoshi, Atsuhiro Yasuhara, Mutsumi Ito, Osamu Akasaka, Morio Nakamura, Ichiro Nakachi, Michiko Koga, Keiko Mitamura, Kazuma Yagi, Kenji Maeda, Hideaki Kato, Masanori Nojima, David Pattinson, Takayuki Ogura, Rie Baba, Kensuke Fujita, Hiroyuki Nagai, Shinya Yamamoto, Makoto Saito, Eisuke Adachi, Junichi Ochi, Shin-ichiro Hattori, Tetsuya Suzuki, Yusuke Miyazato, S. Chiba, Moe Okuda, Jurika Murakami, Taiki Hamabata, Kiyoko Iwatsuki‐Horimoto, Hideaki Nakajima, Hiroaki Mitsuya, Norio Omagari, Norio Sugaya, Hiroshi Yotsuyanagi, Yoshihiro Kawaoka - EClinicalMedicine 2021 cited by 169

  15. GRL-0920, an Indole Chloropyridinyl Ester, Completely Blocks SARS-CoV-2 Infection

    Authors: Shin-ichiro Hattori, Nobuyo Higshi-Kuwata, Jakka Raghavaiah, Debananda Das, Haydar Bulut, David A. Davis, Yuki Takamatsu, Kouki Matsuda, Nobutoki Takamune, Naoki Kishimoto, Tadashi Okamura, Shogo Misumi, Robert Yarchoan, Kenji Maeda, Arun K. Ghosh, Hiroaki Mitsuya - mBio 2020 cited by 79

  16. Droplet digital PCR assay provides intrahepatic HBV cccDNA quantification tool for clinical application

    Authors: Sanae Hayashi, Masanori Isogawa, Keigo Kawashima, Kyoko Ito, Natthaya Chuaypen, Yuji Morine, Mitsuo Shimada, Nobuyo Higashi‐Kuwata, Takehisa Watanabe, Pisit Tangkijvanich, Hiroaki Mitsuya, Yasuhito Tanaka - Scientific Reports 2022 cited by 16

  17. 3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro.

    Authors: Hiroaki Mitsuya, Kent J. Weinhold, P A Furman, M H St Clair, Sandra Nusinoff Lehrman, Robert C. Gallo, Dani P. Bolognesi, David W. Barry, S Broder - National Academy of Sciences, Proceedings of the National Academy of Sciences 1985 cited by 1,851

  18. Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase.

    Authors: P A Furman, James A. Fyfe, M H St Clair, Kent J. Weinhold, Janet L. Rideout, George A. Freeman, Sandra Nusinoff Lehrman, Dani P. Bolognesi, S Broder, Hiroaki Mitsuya - National Academy of Sciences, Proceedings of the National Academy of Sciences 1986 cited by 1,349

  19. Diverse Transcriptional Response of CD4+ T Cells to Stromal Cell-Derived Factor (SDF)-1: Cell Survival Promotion and Priming Effects of SDF-1 on CD4+ T Cells

    Authors: Yasuhiro Suzuki, Monzur Rahman, Hiroaki Mitsuya - The Journal of Immunology 2001 cited by 177

  20. Mechanism of Inhibition of HIV-1 Reverse Transcriptase by 4′-Ethynyl-2-fluoro-2′-deoxyadenosine Triphosphate, a Translocation-defective Reverse Transcriptase Inhibitor

    Authors: Eleftherios Michailidis, Bruno Marchand, Eiichi Kodama, Kamlendra Singh, Masao Matsuoka, Karen A. Kirby, Emily Ryan, Ali M. Sawani, Éva Nagy, Noriyuki Ashida, Hiroaki Mitsuya, Michael A. Parniak, Stefan G. Sarafianos - Journal of Biological Chemistry 2009 cited by 138

  21. 2′-Deoxy-4′-C-ethynyl-2-halo-adenosines active against drug-resistant human immunodeficiency virus type 1 variants

    Authors: Atsushi Kawamoto, Eiichi Kodama, Stefan G. Sarafianos, Yasuko Sakagami, Satoru Kohgo, Kenji Kitano, Noriyuki Ashida, Yuko Iwai, Hiroyuki Hayakawa, Hirotomo Nakata, Hiroaki Mitsuya, Eddy Arnold, Masao Matsuoka - The International Journal of Biochemistry & Cell Biology 2008 cited by 125

  22. Structure–Activity Relationship Studies of SARS-CoV-2 Main Protease Inhibitors Containing 4-Fluorobenzothiazole-2-carbonyl Moieties

    Authors: Kohei Tsuji, Takahiro Ishii, Takuya Kobayakawa, Nobuyo Higashi‐Kuwata, Kouki Shinohara, Chika Azuma, Yutaro Miura, Hiroki Nakano, Naoya Wada, Shin‐ichiro Hattori, Haydar Bulut, Hiroaki Mitsuya, Hirokazu Tamamura - Journal of Medicinal Chemistry 2023 cited by 24

  23. Novel bis -Tetrahydrofuranylurethane-Containing Nonpeptidic Protease Inhibitor (PI) UIC-94017 (TMC114) with Potent Activity against Multi-PI-Resistant Human Immunodeficiency Virus In Vitro

    Authors: Yasuhiro Koh, Hirotomo Nakata, Kenji Maeda, Hiromi Ogata, Geoffrey Bilcer, Thippeswamy Devasamudram, John Kincaid, Péter Boross, Yuan-Fang Wang, Yunfeng Tie, Patra Volarath, L. Gaddis, Robert W. Harrison, Irene T. Weber, Arun K. Ghosh, Hiroaki Mitsuya - Antimicrobial Agents and Chemotherapy 2003 cited by 366

  24. Kinetic Characterization and Cross-Resistance Patterns Of HIV-1 Protease Mutants Selected under Drug Pressure

    Authors: Sergei Gulnik, Leonid I. Suvorov, Beishan Liu, Betty Yu, Barry Anderson, Hiroaki Mitsuya, John W. Erickson - Biochemistry 1995 cited by 266